Recombinant Vaccines Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)

$ PRICE - $ 3,000.00$ 8,900.00

Recombinant Vaccines Market: By Type (Subunit and Live Attenuated), By Route of Administration (Parenteral and Oral), By Disease Indication (Human Papillomavirus, Hepatitis B, Rotavirus, Herpes Zoster, Meningococcal B, and Others) By Distribution Channel (Hospitals & Retail Pharmacies, Government Suppliers, and Others) and Geography

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The recombinant vaccines market is estimated to be valued at USD 11,507.3 million in 2021, and it is expanded to grow at a significant CAGR of 5.3% over 2022-2028. The main factors driving the global recombinant vaccine market are the full-fledged recombinant properties in providing the effectiveness and safety of the patient getting immunized. Additionally, the increasing prevalence of viral diseases in countries worldwide is anticipated to boost the market. The growing population and strict regulations for infant immunization are projected to drive the overall market. Another significant driving force is the improvement of technology in the fields of recombinant DNA technology, genetics, and proteomics, which is boosting vaccination R&D. As a result, the number of clinical trials is increasing. Based on the Route of Administration, the parenteral segment has a significant share of the global recombinant vaccines market with a share of 87.3% in 2021 the global market and is projected to grow at 4.9% CAGR from 2022 – 2028. The parenteral vaccines, such as enhanced potency inactivated polio vaccine, Haemophilus influenzae type B, hepatitis B virus (HBV), and other non-mucosal vaccines, have been highly effective in preventing systemic disease during subsequent exposure to natural infection.

Recent Market Developments:

In Jan 2021, Merck, a leading science and technology company, announced the acquisition of Amptek, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO). The deal strengthens Merck’s capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments, and diagnostics applicable in Covid-19 and many other diseases. Financial terms were not disclosed.

In April 2021, Sanofi and GSK announce that they have signed a letter of intent to enter collaboration to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.

Recombinant Vaccines Market

MARKET SUMMARY
-
5.3% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 5.3%
  • Largest Market– North-America
  • Fastest Growing Market– Europe

Recombinant Vaccines Market

  • The recombinant vaccines market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The recombinant vaccines market is segmented based on type, route of administration, disease indication, distribution channel, and geography.
Key Players
  • Bayer AG
  • Sanofi SA
  • Pfizer Inc.
  • Bharat Biotech.
  • GC Biopharma.
Recombinant Vaccines Market

Dynamics

The market for recombinant vaccines is predicted to develop as the incidence of zoonotic diseases rises, and new technologies emerge. Furthermore, the marketplace is likely to be fueled by continued investment in vaccine research and development and growing public awareness of vaccines. The high cost associated with recombinant vaccines would inhibit the market.


North-America Got Significant Share

Recombinant Vaccines Market

The recombinant vaccine market is likely to be dominated by North America. Continued R&D investment and the presence of key market players boost the growth of the recombinant vaccines market in North America. In addition, the rapid adoption of efficient vaccines across the region and the availability of advanced molecular & genetic engineering instruments also boost the market. Due to rising urbanization, industrialization, and building industry expansion, Asia-Pacific accounted for a large share. On the other hand, Europe is projected to witness significant growth in the market due to the lower prevalence of disease indications and lesser adoption of immunization policies in underdeveloped Europe. The high growth countries, including the UK, France, and Germany, would contribute to the growth of the European market.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The recombinant vaccines market report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Recombinant Vaccines Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The CAGR of the recombinant vaccines market is 5.3% over the forecast period (2022 – 2028)

 

 

Merck KGaA, Novartis AG, GlaxoSmithKline Plc., GC Biopharma, Bayer AG, Sanofi SA, Pfizer Inc.

 

The Europe is the fastest-growing region for the recombinant vaccines market


Report

Company Profile

  • Merck KGaA
  • Novartis AG
  • GlaxoSmithKline Plc.
  • GC Biopharma
  • Bayer AG
  • Sanofi SA
  • Pfizer Inc.
  • Bharat Biotech.

Description

The recombinant vaccines market is estimated to be valued at USD 11,507.3 million in 2021, and it is expanded to grow at a significant CAGR of 5.3% over 2022-2028. The main factors driving the global recombinant vaccine market are the full-fledged recombinant properties in providing the effectiveness and safety of the patient getting immunized. Additionally, the increasing prevalence of viral diseases in countries worldwide is anticipated to boost the market. The growing population and strict regulations for infant immunization are projected to drive the overall market. Another significant driving force is the improvement of technology in the fields of recombinant DNA technology, genetics, and proteomics, which is boosting vaccination R&D. As a result, the number of clinical trials is increasing. Based on the Route of Administration, the parenteral segment has a significant share of the global recombinant vaccines market with a share of 87.3% in 2021 the global market and is projected to grow at 4.9% CAGR from 2022 – 2028. The parenteral vaccines, such as enhanced potency inactivated polio vaccine, Haemophilus influenzae type B, hepatitis B virus (HBV), and other non-mucosal vaccines, have been highly effective in preventing systemic disease during subsequent exposure to natural infection.

Recent Market Developments:

In Jan 2021, Merck, a leading science and technology company, announced the acquisition of Amptek, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO). The deal strengthens Merck’s capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments, and diagnostics applicable in Covid-19 and many other diseases. Financial terms were not disclosed.

In April 2021, Sanofi and GSK announce that they have signed a letter of intent to enter collaboration to develop an adjuvanted vaccine for COVID-19, using innovative technology from both companies, to help address the ongoing pandemic.

Reviews

There are no reviews yet.

Be the first to review “Recombinant Vaccines Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis (2017-2021) and Forecast (2022-2028)”

Your email address will not be published. Required fields are marked *

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX